MG
DGX icon

Michael Gelband’s Quest Diagnostics DGX Stock Holding History

Michael Gelband’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,802
Closed -$833K – 1666
2025
Q4 		$833K Sell
4,802
-6,348
-57% -$1.16M 0.01% 1057
2025
Q3 		$2.12M Buy
+11,150
New +$1.98M 0.02% 717
2024
Q4 		– Sell
-254,598
Closed -$39.5M – 1635
2024
Q3 		$39.5M Buy
254,598
+128,314
+102% +$19.2M 0.24% 63
2024
Q2 		$17.3M Buy
+126,284
New +$17.3M 0.12% 151
2024
Q1 		– Sell
-93,700
Closed -$12.9M – 1590
2023
Q4 		$12.9M Buy
93,700
+60,309
+181% +$7.93M 0.08% 170
2023
Q3 		$4.07M Sell
33,391
-50,625
-60% -$6.75M 0.04% 427
2023
Q2 		$11.8M Buy
84,016
+21,192
+34% +$2.92M 0.1% 214
2023
Q1 		$8.89M Buy
62,824
+50,332
+403% +$7.2M 0.07% 317
2022
Q4 		$1.95M Sell
12,492
-17,704
-59% -$2.54M 0.03% 654
2022
Q3 		$3.71M Sell
30,196
-12,902
-30% -$1.7M 0.05% 515
2022
Q2 		$5.73M Buy
43,098
+23,425
+119% +$3.19M 0.07% 363
2022
Q1 		$2.69M Sell
19,673
-13,806
-41% -$1.92M 0.03% 639
2021
Q4 		$5.79M Sell
33,479
-2,020
-6% -$307K 0.06% 381
2021
Q3 		$5.16M Buy
35,499
+20,943
+144% +$3.06M 0.07% 387
2021
Q2 		$1.92M Buy
14,556
+2,749
+23% +$360K 0.02% 703
2021
Q1 		$1.51M Sell
11,807
-11,651
-50% -$1.44M 0.02% 693
2020
Q4 		$2.79M Buy
23,458
+12,208
+109% +$1.49M 0.03% 417
2020
Q3 		$1.29M Buy
11,250
+642
+6% +$75.9K 0.03% 577
2020
Q2 		$1.21M Buy
10,608
+5,335
+101% +$566K 0.03% 647
2020
Q1 		$423K Buy
+5,273
New +$546K 0.02% 548

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Michael Gelband's DGX Position: Q1 2026 in Review

Michael Gelband sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 4,802 shares — an estimated $833K sold.

Michael Gelband first reported a position in DGX in Q1 2020 and held it in 20 quarters. The position peaked at $39.5M in Q3 2024. 1,067 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Michael Gelband reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 4,802 Quest Diagnostics shares in Q1 2026, an estimated $833K.
  • Michael Gelband first reported a position in Quest Diagnostics in Q1 2020 and held it in 20 quarters.
  • Michael Gelband's Quest Diagnostics position peaked at $39.5M in Q3 2024.
  • 1,067 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.